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A crucial tenet of the prion hypothesis is that misfold-
ing of the prion protein (PrP) induced by mutations
associated with familial prion disease is, in an other-
wise normal mammalian brain, sufficient to generate
the infectious agent. Yet this has never been demon-
strated. We engineered knockin mice to express a
PrP mutation associated with a distinct human prion
disease, fatal familial insomnia (FFI). An additional
substitution created a strong transmission barrier
against pre-existing prions. The mice spontaneously
developed a disease distinct from that of other
mouse prion models and highly reminiscent of FFI.
Unique pathology was transmitted from FFI mice to
mice expressing wild-type PrP sharing the same
transmission barrier. FFI mice were highly resistant
to infection by pre-existing prions, confirming infec-
tivity did not arise from contaminating agents.
Thus, a single amino acid change in PrP is sufficient
to induce a distinct neurodegenerative disease and
the spontaneous generation of prion infectivity.
INTRODUCTION
Prion diseases are a heterogeneous group of devastating and
fatal neurodegenerative diseases affecting animals (chronic
wasting disease in deer and elk, scrapie in goats and sheep,
and ‘‘mad cow’’ disease in cattle) and humans (Creutzfeldt-Ja-
kob disease, CJD; Gerstmann-Stra¨ussler-Scheinker syndrome,
GSS; fatal familial insomnia, FFI; and kuru) (Aguzzi et al., 2007;
Prusiner, 1998). Sponge-like vacuolation, neuronal loss, and
PrP deposits are commonly present, but clinical symptoms
and the types and distribution of neural lesions vary between
different prion diseases (Prusiner, 1998). Prion diseases are
highly unusual in that they can be acquired by infection, can
occur sporadically, or can be inherited (Prusiner, 1998).
The agents most widely believed to cause these diseases are
known as prions (Prusiner, 1982). Prions were originally defined
as proteinaceous infectious particles and later found to consist438 Neuron 63, 438–450, August 27, 2009 ª2009 Elsevier Inc.primarily of the misfolded host-encoded PrP protein (Prusiner,
1982, 1998). The protein-only hypothesis of infectivity is sup-
ported by many lines of evidence (Castilla et al., 2005; Collinge
and Clarke, 2007; Deleault et al., 2007; Legname et al., 2004),
yet an important element remains controversial (Chesebro,
2003; Manuelidis, 2007; Somerville, 2002; Weissmann and
Flechsig, 2003). The hypothesis holds that a misfolded, self-
templating form of PrP is the basis of infectivity. Further, PrP
mutations that are associated with familial human prion disease
produce infectivity by increasing the likelihood of the misfolding
event. However, the crucial prediction that a disease-associated
PrP mutation can, in fact, spontaneously generate infectivity has
never been experimentally demonstrated. Of the many trans-
genic mouse models that have been studied, only one—
expressing a PrP mutation associated with GSS—has been sug-
gested to produce spontaneous infectivity (Hsiao et al., 1990,
1994). However, subsequent work established that brain
homogenates of these mice are more properly described as
‘‘accelerating a pre-existing disease’’ in the GSS recipient mice
(Nazor et al., 2005). Disease could not be transmitted to mice
expressing wild-type PrP. Therefore, the countervailing theory,
that PrP mutations simply make animals more susceptible to
infection by an exogenous agent, remains viable (Barron et al.,
2001; Chesebro, 2003; Manson et al., 1999; Manuelidis, 2007;
Weissmann and Flechsig, 2003).
To create a unique model of inherited prion disease and deter-
mine if familial PrP mutations can spontaneously give rise to
infectivity, we engineered mice to express a PrP gene carrying
the mouse equivalent of the human FFI mutation. This mutation
was chosen because biophysical studies predict that its propen-
sity to destabilize PrP is in the middle range of disease-associ-
ated PrP mutations (Apetri et al., 2004; Riek et al., 1998) and,
more importantly, it is associated with FFI, a disease with a
clinical spectrum and neuropathology distinct from other prion
diseases (Gambetti and Lugaresi, 1998; Lugaresi et al., 1998).
Distinguishing clinical features of FFI are disruption of the auto-
nomic nervous system (dysautonomia) and a form of insomnia
in which deep, slow-wave sleep is not achieved (Benarroch
and Stotz-Potter, 1998; Gambetti and Lugaresi, 1998; Lugaresi
et al., 1986). (Secondary clinical manifestations include loss of
muscle coordination [ataxia] and seizure-like muscle twitching,
but these are also seen in other prion diseases.) Unlike other
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disease, the most striking neuropathology of FFI occurs in the
thalamus, consisting of neuronal loss and reactive gliosis (Benar-
roch and Stotz-Potter, 1998; Gambetti and Lugaresi, 1998;
Lugaresi et al., 1986, 1998). Furthermore, most prion diseases
demonstrate abundant proteinase K (PK)-resistant forms of
PrP (PrPres) and widespread spongiform degeneration, but FFI
does not (Brown et al., 1995; Little et al., 1986; Lugaresi et al.,
1986; Parchi et al., 1998). Indeed, classification of FFI as a prion
disease was disputed (Little et al., 1986; Lugaresi et al., 1986)
until it was linked to an aspartate-to-asparagine substitution at
codon 178 (D178N) of the PrP gene (Prnp) (Medori et al., 1992)
and shown to be transmissible (Collinge et al., 1995; Tateishi
et al., 1995).
No mouse model fully recapitulates any human disease. But
we hoped that the pathology associated with the FFI mutation
would be both sufficiently reminiscent of the pathology of human
FFI and, most importantly, sufficiently distinct from the pathology
of other mouse prion models to ensure that disease was due to
the FFI-mutated PrP protein. In the event that our mice devel-
oped a transmissible form of the disease, it was necessary to
establish that the mutation didn’t simply make the mouse more
susceptible to contaminating pre-existing prions that might be
present in our laboratory (Chesebro, 2003; Manuelidis, 2007;
Somerville, 2002). Indeed, the familial mutation associated with
GSS (P101L) makes mice more susceptible to prion infection
(Barron et al., 2001; Manson et al., 1999). Hence, we altered
two additional amino acids to introduce a transmission barrier
(species barrier) to pre-existing prions (Scott et al., 1993; Supat-
tapone et al., 2001), substituting two methionines from the wild-
type human sequence for leucine and valine (at aa position 108
and 111) in the wild-type mouse sequence. Humanizing the prion
sequence in this manner provided two additional important
benefits. First it allowed us to distinguish the origin of any infec-
tious material in transmission studies because the substitution
allows recognition by the 3F4 antibody. Second, in previous
transgenic mouse experiments, unmodified human or mouse
sequences were much less efficient in modeling infectious
human prion diseases than human/mouse chimeras that
included the 3F4 epitope (Telling et al., 1995). This may be
because some human sequences facilitate the misfolding that
is presumed to occur with the familial PrP mutations, because
of host-specific PrP::chaperone interactions, or both.
Finally, overexpression of PrP makes mice more prone to
spontaneous disease (Castilla et al., 2004; Westaway et al.,
1994) and makes them more susceptible to prion infection
(Fischer et al., 1996; Sigurdson et al., 2006; Thackray et al.,
2002). Therefore, we used a knockin approach to introduce the
FFI mutation to the Prnp locus. This ensured that the allelic vari-
ants would remain subject to all of the regulatory elements that
normally control the complex expression pattern of PrP (McCor-
mack et al., 2002).
Knockin mice carrying the FFI mutation developed biochem-
ical, physiological, behavioral, and neuropathological abnormal-
ities that were surprisingly similar to FFI in humans and very
different from those of scrapie-infected mice or transgenic
mice expressing other mutant forms of PrP. Remarkably, this
spontaneous disease could be transmitted, and seriallypassaged, to mice expressing physiological amounts of wild-
type PrP with the same human epitope. The FFI mice were highly
resistant to common laboratory strains of mouse scrapie, and
the few mice that did succumb exhibited the characteristics of
mouse scrapie rather than FFI. These data exclude the possi-
bility that the spontaneous FFI disease and its transmissibility
arose from infection with pre-existing prions. Knockin mice
carrying the 3F4 epitope alone never succumbed to sponta-
neous disease. Thus, the single amino acid substitution associ-
ated with FFI in humans causes spontaneous prion disease in
mice. The transmissibility of this genetically initiated disease to
mice not carrying the FFI mutations provides crucial support
for a causal link between PrP misfolding and the spontaneous
generation of a transmissible agent.
RESULTS
Generation of FFI Mice
We generated two strains of mice expressing PrP proteins that
differ only by a single amino acid (D177N), the mouse equivalent
of the mutation associated with human FFI (Figure 1A). Both
proteins also carried the two amino acid human sequence
substitution (L108M, V111M). In addition to introducing a trans-
mission barrier against mouse scrapie (Scott et al., 1993; Supat-
tapone et al., 2001), this substitution introduced an epitope for
the 3F4 antibody, which does not detect mouse PrP (Kascsak
et al., 1987). These genes were inserted into their normal
genomic context by gene-replacement in mouse embryonic
stem (ES) cells (Figure S1) (Moore et al., 1995; Selfridge et al.,
1992). ES cells were tested for homologous recombination by
PCR (data not shown) and Southern analysis (Figure 1B), and
positive ES cells were used to generate knockin mice, desig-
nated ki-3F4-WT and ki-3F4-FFI. PCR analysis of homozygous
animals amplified the modified allele but not the unmodified,
wild-type (WT) allele (Figure 1B). Western blotting of brain
homogenates showed no 3F4 immunoreactivity in brains of WT
or PrP knockout (KO) mice but did show immunoreactivity in
ki-3F4-WT and ki-3F4-FFI mice (Figure 1C).
PrP modified only by the 3F4 epitope (PrP3F4WT) was ex-
pressed at the same level as unmodified wild-type PrP (PrPWT),
as shown by their equal reactivity with 6H4 antibody (Figure 1C).
It also produced identical banding patterns as PrPWT, before and
after treatments with enzymes diagnostic for trafficking though
the endoplasmic reticulum (ER) and Golgi (Figure 1D). Both
proteins were sensitive to PNGaseF, indicating they had entered
the ER and became glycosylated, and were resistant to endogly-
cosidaseH, indicating they had trafficked to the Golgi for further
sugar modification. Therefore, our gene-targeting approach and
the introduction of the 3F4 epitope did not cause any unintended
changes to PrP levels or trafficking.
PrP that carried both the 3F4 epitope and the D177N substitu-
tion (PrP3F4FFI) was, like PrPWT and PrP3F4WT, sensitive to PNGa-
seF but not endoglycosidaseH, indicating it too enters the ER
and is trafficked to the Golgi. However, PrP3F4FFI was expressed
at reduced levels, as predicted for a protein prone to misfolding
(Apetri et al., 2004; Riek et al., 1998) (Figure 1C). Importantly, as
seen in humans with FFI (Parchi et al., 1998), the faster-migrating
unglycosylated form of PrP was nearly absent (Figure 1C),Neuron 63, 438–450, August 27, 2009 ª2009 Elsevier Inc. 439
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translationally modified in mice in the same distinct manner as
it is in humans.
Figure 1. Modification of PrP Gene and Protein by Gene Targeting
(A) Schematic of modifications made to the Prnp locus, not to scale. Horizontal
black line represents double-stranded DNA; large gray box represents exon 3
containing all modifications, including the mutation of interest and a new
BamHI site (‘‘B’’) and small inserts for PCR genotyping (small gray box topped
by ‘‘i’’ and flanked by arrows).
(B) Analysis of genome manipulation. Top, Southern analysis of mouse ES cells
using BamHI and a probe (P) that does not anneal to the targeting vector. WT,
untargeted DNA, targeted, indicates ES clones with knockin alleles and a new
5 kilobase band (*). (Left) Bars indicate 10, 8, 6, and 5 kb. (Bottom) PCR anal-
ysis of mouse tail tip DNA from wild-type (WT), heterozygous (het), and homo-
zygous knockin (hom) mice. The product derived from the knockin allele is
indicated by *. The reduced migration rate of the highest band in lane two is
the result of an open loop in heteroduplex PCR products. (Left) Bars indicate
250 and 200 bp.
(C) Western blot of KO (PrP knockout), WT, ki-3F4-WT, and ki-3F4-FFI whole-
brain samples, probed with 3F4 PrP Ab, which detects only PrP that has been
engineered to include the 3F4 epitope (top), probed with 6H4 antibody, which
detects all mouse PrP (middle), or with an actin antibody as a loading control
(lower). Unglycosylated PrP is apparently absent in ki-3F4-FFI brains (top two
blots, *).
(D) Biochemical analysis of posttranslational modification of PrP. Western blot
of untreated and endoglycosidase H (endoH) and PNGaseF treated samples,
probed with SAF32 anti-PrP (top) from KO, WT, ki-3F4-WT (3F4/WT), and
ki-3F4-FFI (3F4/FFI) mice. (Left) Bars indicate 37 and 25 kDa. The same blot
was stripped and probed with an antibody specific for adhesion molecule on
glia protein (AMOG), a protein sensitive to both enzymes (lower). This control
indicates equal loading and activity of EndoH and PNGaseF. (Left) Bars
indicate 50, 37, and 25 kDa.440 Neuron 63, 438–450, August 27, 2009 ª2009 Elsevier Inc.Neuropathology of ki-3F4-FFI Mice
Homozygous ki-3F4-WT mice did not get sick and exhibited no
neuropathology. Heterozygous ki-3F4-FFI mice also appeared
normal, although they were examined less thoroughly. This
was expected, as humans carry the FFI mutation for decades
prior to disease onset. We therefore focused on homozygous
mice to increase gene dosage, a standard practice for knockin
mice modeling neurodegenerative diseases that require many
years to develop in humans (Lin et al., 2001), and since homozy-
gous carriers of prion mutations develop disease faster than
heterozygotes (Simon et al., 2000). Many of the homozygous
ki-3F4-FFI mice lived as long as ki-3F4-WT mice, but all devel-
oped profound neuropathology and behavioral abnormalities.
To visualize the effects of the FFI mutation on overall brain struc-
ture in vivo, we employed a manganese-enhanced magnetic
resonance imaging technique (Aoki et al., 2004; H.F. et al.,
unpublished data). In contrast with age-matched WT and
ki-3F4-WT controls, at 16 months many ki-3F4-FFI mice had
a flattened or concave motor cortex and an atrophied cerebellum
(Figures 2A and S2). The ventricles were also greatly enlarged
(Figure 2A), consistent with atrophy of underlying neural nuclei.
Degenerated cerebella (Almer et al., 1999; Bar et al., 2002; Man-
etto et al., 1992; Sasaki et al., 2005) and dilated ventricles (Bar
et al., 2002; Sasaki et al., 2005) have also been reported in
human FFI cases. Most importantly, abnormalities of the thal-
amus were prominent (Figure 2A). This region of the brain, in
addition to other critical brain functions, is thought to be impor-
tant for sleep regulation (Huguenard and McCormick, 2007;
Steriade and Timofeev, 2003). Thalamic damage is a hallmark
of human FFI (Lugaresi et al., 1986).
Paraffin-embedded brain sections were stained with hema-
toxylin and eosin (H&E). Gross examination revealed enlarged
ventricles (20 months, Figure 2B) and vacuolization, which
was restricted to the deep cerebellar white matter (16 months,
Figure S5). We also employed immunohistochemistry (IHC) for
glial fibrillary acidic protein (GFAP) to detect reactive gliosis, a
conventional marker of neurodegeneration. We found strong
GFAP immunostaining in the deep white matter of the cere-
bellum (n = 16 of 24, 16 months), especially in areas with
vacuolization (Figure 2C) and also found strong GFAP staining
in the thalamus first detected at 12 months (n = 24 of 24,
Figure 2D). In contrast, ki-3F4-WT mice lacked this abnormal
GFAP staining both in the cerebellum (n = 12; p < 0.0005; Fisher’s
exact) and thalamus (n = 12; p < 0.0001). Closer examination of
H&E-stained sections revealed areas of severe neuronal loss in
the thalamus (18 months, Figure 2E). As a complementary
approach, with low-power magnification we detected severe
loss of thalamic neurons by examining 30 mm thick sections
stained with a Nissl-specific dye (18 months, Figure S6).
Thus, ki-3F4-FFI mice developed a unique pattern of neurode-
generation that is distinct from all other neurodegenerative
diseases in humans and scrapie-infected mice but reminiscent
of human FFI (Gambetti et al., 1995; Little et al., 1986; Lugaresi
et al., 1986).
In most prion diseases, PrP acquires biophysical properties
that render it partially resistant to digestion by PK, a state
commonly called PrPres (Prusiner, 1998). FFI, however, charac-
teristically produces very little PrPres and is often not detected
Neuron
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(A) MRI scans show enlarged ventricles (vent), atrophied cerebella (cb, arrow-
heads), and reduced signal intensity in the thalamus (thal,*) of ki-3F4-FFI mice
(right) but not ki-3F4-WT mice (left).
(B) Low magnification of H&E-stained brain sections shows enlarged ventricles
in an FFI mouse (right, arrow and V) above the hippocampus (H) not present in
ki-3F4-WT mice (left). Arrows in (A) bottom right and (B) right correspond to the
same unusual gap or ventricle due to cortical atrophy.
(C) GFAP immunohistochemistry (GFAP) shows reactive gliosis (dark-brown
staining) and vacuolization (white rounded spots inside the GFAP-stained
area) in the cerebellar granular (g) and white matter (wm) in ki-3F4-FFI brains(Brown et al., 1995; Medori et al., 1992; Parchi et al., 1998; Zar-
ranz et al., 2005). In brains of spontaneously sick ki-3F4-FFI
mice, standard immunohistochemical experiments (data not
shown) and western blotting experiments also using standard
conditions failed to demonstrate PrPres (Figure 2F). We also did
not detect distinct PrP conformers using conformation-depen-
dent immunoassays, histoblots, phosphotungstate precipita-
tions, semidenaturing detergent-agarose gel electrophoresis,
luminescent conjugated polymers, and several immunohisto-
chemical methods (utilizing various conditions of PK digestions,
denaturants, and autoclaving or microwaving steps, data not
shown). However, when 20 mg of total brain homogenates
from 2-year-old ki-3F4-FFI mice was PK digested and concen-
trated by tricholoracetic acid precipitation, a small amount of
PrPres was detected (Figure 2F). Therefore, the unusual
biochemical characteristic of producing low amounts of PrPres
in human FFI is also recapitulated in this mouse model.
Clinical Abnormalities of ki-3F4-FFI Mice
Behavioral changes were detected using automated mouse
behavioral analysis (AMBA), which employs 24 hour video
recordings to classify activities of mice in solitary cages (Steele
et al., 2007). Videos are collected at a rate of 30 frames per
second for 24 hr (2.6 3 10E6 frames per session) and a series
of six frames is sufficient to classify individual behaviors. This
system allows the detection of phenotypic changes prior to overt
abnormalities by quantifying changes in a large number of spon-
taneous activities and allowing the assessment of undisturbed
nocturnal behavior (the active period for the mouse). Employing
this technology previously, we uncovered an unexpected pheno-
type in scrapie-infected mice: during the night, they travel inces-
santly, covering ten times more distance than control mice
(Steele et al., 2007). Here, we compared WT, ki-3F4-WT, and
ki-3F4-FFI mice throughout their lives, with several early time
points to establish a baseline before disease onset. WT and
ki-3F4-WT mice behaved similarly throughout their lifetimes,
indicating that neither the mixed genetic background we em-
ployed nor the 3F4 epitope caused behavioral abnormalities
(Figure S7).
Ki-3F4-FFI mice developed striking age-related changes in
behavior. A few individual behaviors, plotted over the course of
24 hr for mice at 16 months of age are presented in Figure 3A.
A composite of all the data for the different groups of mice is
(right) but not ki-3F4-WT mice (left). The molecular (m) and Purkinge (P) cell
layers are labeled for orientation.
(D) Reactive gliosis in the thalamus in ki-3F4-FFI mice (right) but not ki-3F4-WT
mice (left).
(E) H&E shows loss of neurons (arrow, right) and increased numbers of glia
(arrowheads, right) in the thalamus of ki-3F4-FFI mice compared to the
thalamus of age-matched ki-3F4-WT mice (left).
(F) Western analysis of brain homogenates (5 mg/ml protein) from aged WT,
ki-3F4-WT (3F4/WT), or three sick ki-3F4-FFI mice (3F4/FFI), incubated for
1 hr with (+) or without (–) 25 mg/ml PK and probed with 3F4 (left blot).
PK-digested samples were also concentrated prior to western blotting (right
blot). Bars left of each blot indicate molecular weight in kDa. Faint bands
with an apparent molecular weight of 25 kDa are likely not PrP since it was
detected in WT mice with the 3F4 antibody. Each lane was loaded with
50 mg of total brain protein for the left blot; 2 mg of total protein for PK+ lanes
and 50 mg for PK– lanes for the right blot.Neuron 63, 438–450, August 27, 2009 ª2009 Elsevier Inc. 441
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ki-3F4-FFI Mice
(A) AMBA data of ki-3F4-FFI mice (blue lines)
compared to ki-3F4-WT mice (red lines) at
16 months of age show night-time-specific differ-
ence for distance traveled (top), fully reared
(second from top), twitch at rest (third from top),
and rest (bottom). Horizontal axes mark 24 one
hour bins. The gray shading indicates the time at
which lights are off (bins 2–13). p values are
symbolized by *p < 0.05, #p < 0.01, $p < 0.001.
Vertical error bars depict quartiles, and connecting
lines intersect at the median.
(B) A phenotypic array representing median differ-
ences between ki-3F4-WT and ki-3F4-FFI mice for
specific behaviors, labeled on the left. Yellow tiles
depict comparisons for which the ki-3F4-FFI mice
performed the specific activity more than ki-3F4-
WT, and cyan tiles represent comparisons where
the ki-3F4-FFI mice performed the specific activity
less than ki-3F4-WT mice. The brightness corre-
sponds to the magnitude of the difference (a scale
is below the arrays). The age in months is labeled
directly below the array. The number of animals
for each comparison is immediately above the
array where ‘‘n1’’ rows indicate the number of ki-
3F4-WT mice and ‘‘n2’’ rows indicate the number
of ki-3F4-FFI mice.
(C) Body temperatures (Tb) were measured in five
ki-3F4-WT and five ki-3F4-FFI mice at an accuracy
of 0.067C, using an implanted recorder. The Tb of
a ki-3F4-WT (left WT individual 1, red) is plotted
over the average Tb of five ki-3f4-WT mice (left,
WT average, black). Two ki-3F4-FFI mice (middle
and left, FFI individual 1 and 2, respectively) are
depicted by blue traces and are plotted over the
same WT average line. FFI mouse 1 had a widely
fluctuating Tb while FFI mouse 2 had a persistently
warm Tb.presented in Figure 3B in a ‘‘phenotypic array’’ format. The data
for each behavior in a 24 hr period is collapsed into one tile. Each
tile represents the median difference between the two genotypes
for that behavior, with cyan indicating behaviors that decreased
and yellow indicating behaviors that increased in ki-3F4-FFI mice
compared to ki-3F4-WT mice; the brightness of the color corre-
sponds to the magnitude of the difference between the two
groups.
Behavioral abnormalities in ki-3F4-FFI mice were most prom-
inent at night (Figure 3A) but stood in sharp contrast to those of
scrapie-infected mice. Rather than traveling more than controls
(Steele et al., 2007), ki-3F4-FFI mice spent less time traveling
and covered less distance (Figure 3A). They also spent less
time jumping, hanging from the top of the cage, and rearing on
their hind limbs (fully reared) than control mice, indicating a
reduction in overall activity (Figures 3A and 3B), again opposite
to scrapie-infected mice (Steele et al., 2007). Strikingly, ki-3F4-
FFI mice had higher scores of awaken (activity that ends rest
periods) and twitch (activity that disrupts rest periods), metrics442 Neuron 63, 438–450, August 27, 2009 ª2009 Elsevier Inc.of sleep interruption, starting as early as 5 months of age
(Figure 3B). This occurred far before overt physical or behavioral
abnormalities were apparent without AMBA (which occurred
only at 12–16 months). Twitching during rest continued to
increase, and by 16 months ki-3F4-FFI mice exhibited extended
periods of inactivity, lying on the cage floor (specifically in the
night phase) as if they were exhausted from lack of uninterrupted
sleep (‘‘rest,’’ Figures 3B and 3C).
Sleep state is tightly coupled with core body temperature (Tb),
which rises during wake periods and declines during sleep (Mo-
chizuki et al., 2006). Human FFI typically includes dysautonomia
with abnormal Tb regulation (Lugaresi et al., 1986; Sasaki et al.,
2005). To measure Tb, we implanted small temperature-re-
cording devices (Mochizuki et al., 2006) into the peritoneal cavity
of five mice of each genotype at 16 months and measured Tb at
5 min intervals for 10 days.
Tb fluctuated over a much wider range in ki-3F4-FFI mice than
in ki-3F4-WT mice, routinely reaching below 35C for four of the
ki-3F4-FFI mice (Figures 3C and S8). The fifth mouse was instead
Neuron
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measured by AMBA and the improperly controlled Tb suggest
that ki-3F4-FFI mice do not enter deep sleep. Humans with FFI
typically appear hypersomnic because they enter the early
stages of sleep yet are unable to enter deep, slow-wave sleep
(Lugaresi et al., 1986, 1998). Thus, ki-3F4-FFI mice developed
both activity and temperature homeostasis abnormalities remi-
niscent of human FFI.
Ki-3F4-FFI Disease Is Transmissible
To test for the presence of a transmissible agent, we injected
a relatively conservative amount of brain homogenate (30 ml
dose of material diluted 1 to 100 m/v), intracranially. We em-
ployed recipient mice that expressed no PrP (KO) (Bueler et al.,
1992; Manson et al., 1994), normal levels of PrP (WT or ki-3F4-
WT), or high levels of PrP (Tga20) (Fischer et al., 1996).
The 3F4 epitope itself has been repeatedly tested and never
found to produce infectious material on its own (Scott et al.,
1993; Supattapone et al., 2001). However, to control for the
possibility that the 3F4 epitope caused mouse PrP to spontane-
ously misfold in the knockin configuration employed here, we
aged ki-3F4-WT mice for 2 years to maximize the opportunity
for spontaneous conversion. All genotypes injected with brain
homogenate from these mice remained healthy until they were
sacrificed in old age (Figures 4A and 4G–4J).
To determine whether mice carrying the FFI mutation on the
3F4 background produced infectivity, we sacrificed three spon-
taneously sick (terminal) mice that had become symptomatic at
different ages. Both Tga20 mice and ki-3F4-WT mice developed
neurodegenerative disease.
Tga20 mice overexpress PrPWT from a randomly integrated
transgene. Although overexpression of PrP can itself lead to
pathology (Castilla et al., 2004; Westaway et al., 1994), Tga20
mice have been extensively characterized, with no spontaneous
pathologies reported (Fischer et al., 1996; Sigurdson et al., 2009;
Thackray et al., 2002). Because the overexpression of PrP accel-
erates the course of disease (Fischer et al., 1996; Thackray et al.,
2002), Tga20 mice are commonly used to test for the presence of
infectious agents. Moreover, Tga20 mice are sensitive to prions
with heterologous sequences (Sigurdson et al., 2006, 2009).
When injected with brain homogenates from spontaneously
sick ki-3F4-FFI mice, they developed ataxia, kyphosis (hunched
back posture), pruritus (persistent itch), dermatitis, reduced
body condition, and a highly unusual paroxysmal hind limb
tremor (Figure 4B and Movie S1). Neuropathological examina-
tion of injected Tga20 mice revealed intense GFAP immunoreac-
tivity in the thalamus and enlargement of ventricles (Figures 4G
and 4H). Importantly, homogenates made from all three of the
spontaneously sick ki-3F4-FFI mice we tested produced similar
physical symptoms, behavior, pathology, and time course (p >
0.1, log-rank; statistical tests for FFI transmission studies can
be found in Table S1). Tga20 mice either not injected or injected
with normal brain homogenates never displayed any of these
abnormalities of behavior (Figure 4A and Movie S2) or histology
(Figure 4H, right). Thus, spontaneously sick ki-3F4-FFI mice
generated a transmissible agent that produced a disease in
Tga20 mice that has many unique features and is distinct from
scrapie.Even more tellingly, ki-3F4-WT mice, expressing normal levels
of PrP, also became sick, developing ataxia, kyphosis, reduced
body condition, and many died prematurely following injection
with homogenates from spontaneously sick ki-3F4-FFI mice
(Figure 4C). Of course, we would not expect the same pathology
in mice suffering the effects of the continuous production of
mutant, misfolding PrP throughout the brain throughout their life-
times (primary FFI disease), as in mice expressing wild-type
protein suffering the effects of a transmissible agent delivered
in a single dose in one location. Indeed, the latter did not exhibit
thalamic damage. They did, however, share other features of
degenerative damage with spontaneously sick ki-3F4-FFI
mice, including the absence of PrPres (data not shown), dilated
ventricles, white matter vacuolization, and increased GFAP
staining in the cerebellum (Figures 4I and 4J). The apparently
different rates of disease onset, though not statistically signifi-
cant (p > 0.5), might reflect different prion titers in the primary
inoculum or the presence of multiple prion strains (Polymenidou
et al., 2005). The spontaneously generated disease of ki-3F4-FFI
mice was caused by the FFI mutation and was transmissible to
mice expressing endogenous levels of PrP.
We then asked if the infectivity observed with ki-3F4-FFI brain
homogenates could be serially transmitted. Brain homogenates
of sick ki-3F4-WT mice that had been injected with brain homog-
enates from spontaneously sick ki-3F4-FFI were injected into
a fresh group of ki-3F4-WT mice. These second-passage recip-
ient mice developed ataxia, kyphosis, reduced body condition,
and died prematurely (Figure 4D). On histological examination,
they had atrophy of subcortical regions and swelling of ventri-
cles, similar to that of spontaneously sick ki-3F4-FFI mice and
yet different from scrapie-infected mice (Figure 4K). Not unex-
pectedly, the precise pathology that developed in mice injected
with brain homogenates from spontaneously sick ki-3F4-FFI
mice depended on the amount and/or sequence of PrP protein
that was being expressed in the recipient animal (i.e., Tga20 or
ki-3F4-WT). But the transmissible nature of the pathology was
unequivocal.
As expected, PrP KO mice injected with brain homogenates
from spontaneously sick ki-3F4-FFI mice remained normal
behaviorally (Figure 4E) and neuropathologically (data not
shown). Thus, as reported for all other transmissible prion
agents, susceptibility to the agent produced by our FFI mice
required that the animals be expressing PrP protein. Notably,
however, wild-type mice injected with these homogenates also
remained healthy (Figure 4F). The fact that transmission to hosts
expressing physiological amounts of PrP required the 3F4
epitope indicates the transmissible agent produced by the FFI
mice was sensitive to transmission barriers, much like typical
prions (Aguzzi et al., 2007; Collinge and Clarke, 2007; Somerville,
2002). Since wild-type mice could not be infected, neither the
ki-3F4-FFI mice nor the inocula derived from their brains were
contaminated by pre-existing agents.
Ki-3F4-FFI Mice Resist Exogenous Prions
The fact that brain homogenates of ki-3F4-FFI mice produced
a disease with properties very different from that caused by
mouse scrapie indicates that they are producing a unique
new strain of prion infectivity. Is the spontaneous misfoldingNeuron 63, 438–450, August 27, 2009 ª2009 Elsevier Inc. 443
Neuron
De Novo Prions in Fatal Familial Insomnia MiceFigure 4. Transmission of Disease from
ki-3F4-FFI Brain Homogenates
(A) Kaplan-Meier plot of Tga20 (square) and
ki-3F4-WT (diamond) mice injected with 30 ml of
1% brain homogenate from 2-year-old ki-3F4-
WT mice. These mice never showed signs of
disease.
(B–E) Kaplan-Meier plots of KO (B), WT (C), Tga20
(D), and ki-3F4-WT (E) mice injected with 30 ml of
1% brain homogenates from three different spon-
taneously sick ki-3F4-FFI mice (FFI #1-3).
(F) Serial passage of ki-3F4-FFI disease from
isolates (30 ml of 1% brain homogenates) derived
from two separate ki-3F4-WT mice injected with
FFI # 1 (E).
(G) Reactive gliosis detected by GFAP IHC was
prominent in the thalamus of tga20 mice injected
with brains of aged ki-3F4-FFI mice (dark staining,
left) but not tga20 mice injected with brains from
aged ki-3F4-WT mice (right).
(H) Enlarged ventricles (left, ‘‘V’’ and arrow) above
the hippocampus (‘‘H’’) were also prominent in
tga20 mice injected with brain homogenates
from aged ki-3F4-FFI mice, but not in tga20 mice
injected with brain homogenates from aged
ki-3F4-WT mice (right).
(I) Reactive gliosis detected by GFAP IHC (darkly
stained area) and vacuolization was prominent in
the white matter of ki-3F4-WT mice injected with
ki-3F4-FFI brain homogenate (left). A ki-3F4-WT
mouse brain injected with brain homogenates
from an aged ki-3F4-WT mouse has only back-
ground levels of GFAP staining and no vacuoliza-
tion (right).
(J) Enlarged ventricle (left, arrow) above the hippo-
campus (Hipp) of a ki-3F4-WT mouse injected with
brain homogenate from a sick ki-3F4-FFI mouse,
not present in ki-3F4-WT mice injected with aged
ki-3F4-WT brains (right).
(K) Enlarged ventricle above the hippocampus of
a ki-3F4-WT mouse injected with brain homoge-
nate from a sick ki-3F4-WT mouse previously in-
jected with ki-3F4-FFI brain homogenate, not
present in ki-3F4-WT mice succumbing to 22L
scrapie prions (right).of the FFI mutant PrP responsible for generating this transmis-
sible agent? Or could the FFI mutation simply have made
carriers more sensitive to an exogenous agent? (Barron et al.,
2001; Chesebro, 2003; Manson et al., 1999; Manuelidis, 2007;
Somerville, 2002; Weissmann and Flechsig, 2003). We em-
ployed the 3F4 epitope from human and hamster PrP in our
experiments because it was reported to produce a transmission
barrier, at least in a randomly integrated transgenic mouse
model (Supattapone et al., 2001). To directly test whether FFI
mice were more susceptible to pre-existing prions, we injected
ki-3F4-WT mice with two different strains of mouse-adapted
scrapie, RML and 22L, the only prion strains that have ever
been employed on our campus. The 3F4 epitope created a
very strong transmission barrier against both strains. Even
when injected with 107 infectious units of 22L or RML, ki-
3F4-WT mice had longer incubation periods than did WT mice
lacking the 3F4 epitope injected with only 50 infectious units
(Figure 5A) (statistical tests for scrapie transmission studies444 Neuron 63, 438–450, August 27, 2009 ª2009 Elsevier Inc.can be found in Table S2). To determine if the 3F4 transmission
barrier applied to alternative routes of infection, 22L scrapie
was also injected intraperitoneally. Again, the 3F4 epitope intro-
duced an extremely strong transmission barrier (Figure 5B).
Therefore, ki-3F4-WT mice were resistant to contamination
from conventional prions but were sensitive to de novo FFI
prions.
Strikingly, mice carrying both the 3F4 epitope and the FFI
mutation had an even stronger transmission barrier against
RML and 22L mouse scrapie (Figure 5C), perhaps because of
primary or tertiary structural differences between the inoculum
and substrate or simply because there was a reduced steady-
state level of PrP in the brain of FFI mice (Figure 1C). Indeed, in
only the most aggressive of six experiments (107 infectious units
of 22L intracranially) did the injection of exogenous mouse prions
shorten the lifespan of ki-3F4-FFI mice (Figure 5D). When the
mice injected with these high levels of prions became sick,
they exhibited behaviors and pathology characteristic of
Neuron
De Novo Prions in Fatal Familial Insomnia MiceFigure 5. FFI Mice Are Not Sensitized to Common Prion Strains
(A–D) Kaplan-Meier survival plots showing the time to terminal illness following injection of 22L or RML strains of mouse-adapted scrapie. Horizontal axes repre-
sent time in days from the date of injection except for panel (D), where it represents the age of the mice (injected at 40 days). (A) Ki-3F4-WT mice had longer
incubation periods following intracranial injection with high titers (hi) of 22L (106.7 infectious doses [ID]) or RML (106.5 ID, empty triangles) compared to similarly
injected WT mice (filled and empty squares, respectively) or WT mice injected with low titers (low) of 22L (101.7 ID, filled diamonds) or RML (101.5 ID, empty
diamonds). (B) Ki-3F4-WT mice are resistant to intraperitoneal injection of 103.7 ID of 22L (filled triangles) compare to WT mice (filled squares). (C) Ki-3F4-FFI
mice injected with either 106.7 ID of 22L (filled circles) or 103.5 ID of RML (empty circles) develop terminal illness later than similarly injected ki-3F4-WT mice (filled
and empty triangles, respectively). (D) Ki-3F4-FFI mice injected with a high dose of 22L (106.7 ID, filled circles) develop a scrapie-like disease and die earlier than
uninjected mice (+) or mice injected with brain homogenate from an aged but otherwise normal mouse (*).
(E) Brain homogenates (5 mg/ml) from WT, ki-3F4-WT (3F4/WT), or ki-3F4-FFI mice (3F4/FFI), terminally sick following injection with 22L mouse scrapie, were
incubated for 1 hr with (+) or without (–) 25 mg/ml PK, and analyzed by western blotting. The 3F4 antibody detects a PrPres species in ki-3F4-WT and ki-3F4-
FFI mice, indicating it is not residual material from the inoculum. SAF32 detected undigested but not PK-digested samples, as the epitope in conventional PrPres
species is typically cleaved by PK.
(F) Kaplan-Meier survival plots showing mice expressing the 3F4 epitope are not sensitized to infection by hamster-derived scrapie strain 263K.scrapie-infected mice and very different from spontaneously
sick 3F4-FFI mice. Moreover, as with scrapie, they produced
easily detectable PrPres with the typical cleavage of the N
terminus (Figure 5E). Since the 3F4 antibody will react with
mouse PrP if carrying the 3F4 epitope but not with unmodified
mouse PrP, this PrPres material must have been synthesized by
the host and was not simply residual material from the scrapie
inoculum, since it reacted with the 3F4 antibody (Figure 5E).
Therefore, PrP3F4FFI is competent to form PrPres when templated
by infection with laboratory prion strains. The dearth of PrPres inour spontaneously sick ki-3F4-FFI mice, and in the animals that
succumbed to the transmissible agent they produced, confirm
that they had not been infected with scrapie.
Finally, although hamsters have never been housed in our
facility nor have we ever passaged hamster scrapie in mice,
we obtained hamster scrapie from the Rocky Mountain Labora-
tory and injected mice intracranially. Ki-3F4-FFI mice died at the
same advanced age as ki-3F4-WT or WT mice (Figure 5F).
Therefore, ki-3F4-FFI mice are not more sensitive to infection
by exogenous prions.Neuron 63, 438–450, August 27, 2009 ª2009 Elsevier Inc. 445
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Our work fulfills a long standing and long unfulfilled prediction of
the prion hypothesis: in the context of an otherwise normal
animal, a familial mutation in PrP is sufficient to cause the de
novo appearance of a transmissible agent for neurodegenera-
tion. Mice carrying the FFI mutation in PrP developed a sponta-
neous disease that was remarkably reminiscent of human FFI.
Due to the fact that our mice produced infectious material, we
were not permitted to perform polysomnography in any of the
facilities we contacted. However, the overt sleep distur-
bances—rest and twitch during rest—we observed in video
recordings and the extreme fluctuations in temperature provide
strong evidence of sleep perturbations and dysautonomia. The
biochemical properties of the PrP protein in our model and the
region-specific neuropathological abnormalities we observed
were also akin to those of FFI.
Importantly, the phenotypic spectrum as a whole was distinct
from those reported for any other PrP mouse models. Further-
more, the mice spontaneously generated prions that encoded
‘‘information’’ that led to distinct neuropathology when injected
into tester animals, a pathology that was partially overlapping
with spontaneous disease and, again, distinct from that of other
previously described transmissible prion strains. Thus, the FFI
mutation was sufficient to specify not only a unique disease state
but a unique self-perpetuating transmissible agent.
PrPres is often considered a hallmark of prion disease and of the
presence of a transmissible agent. However, in many cases of FFI
(Brown et al., 1995; Little et al., 1986; Medori et al., 1992; Zarranz
et al., 2005), as well as in certain other types of prion diseases
(Barron et al., 2007; Haviv et al., 2008; Lasmezas et al., 1997;
Manson et al., 1999), PrPres is not detected. In fact, ina systematic
survey of various forms of genetic and sporadic human prion
diseases, PrPres was readily detectable in several disease types,
but it was not detected in four out of four FFI samples using a rela-
tively large sample of tissue, 0.2 g (Brown et al., 1995). Indeed, it
was only detectable when a full gram of tissue—equivalent to 2.5
whole adult mouse brains—was employed (Brown et al., 1995).
Moreover, transgenic mice expressing human PrP and injected
with human FFI brain homogenates also failed to produce PrPres
despite developing a severe neuropathology (Collinge et al.,
1995). The same mice injected with human CJD homogenates
produced readily detectable PrPres (Collinge et al., 1995). Thus,
negative results with the FFI samples were not just a peculiarity
of that transgenic line. In separate experiments, PrPres was abun-
dant in the brains of humans who carried the FFI mutation but,
notably, in these cases the wild-type allele carried the valine poly-
morphism at codon 129 or the FFI mutant allele itself carried an
octapeptide deletion, (Parchi et al., 1995; Reder et al., 1995; Ta-
teishi et al., 1995; Telling et al., 1996). Since our mice lacked these
sequence differences, we predicted they would not generate
high levels of PrPres if they accurately modeled the human
disease. This prediction was fulfilled. Whether the small amount
of PrPres we detect after concentrating brain homogenates
constitutes the infectious agent in our mice or some other as
yet uncharacterized species remains to be determined.
One suggestion from our work is that other mutations in PrP,
which are associated with distinct disease pathologies in446 Neuron 63, 438–450, August 27, 2009 ª2009 Elsevier Inc.humans, might be expected to give rise to their own transmis-
sible agents. However, several lines of mice expressing PrP
with various familial mutations have been reported, and none
have been found to produce a transmissible agent. In fact, this
failure has been widely cited as evidence against the prion
hypothesis (Chesebro, 2003; Manuelidis, 2007; Somerville,
2002). Given our positive result, why might these other experi-
ments have failed? One possibility is that most of these models
employ randomly integrated transgenes, in which a mutant PrP
allele, often carrying only a small fragment of the large and
complex PrP promoter, integrates into a random position of
the genome, with a variable number of copies. This approach
has been employed because it is far less labor intensive than
the production of knockin mice. Further, the integration of
multiple copies (a characteristic of the method) allows for unusu-
ally high levels of PrP expression, which would quite reasonably
be expected to increase the likelihood of conformational conver-
sion. But the variable expression patterns obtained with these
transgenes have contributed to highly variable phenotypes that
often don’t mimic human disease. Some lines are disease-free
despite overall high PrP expression levels (DeArmond et al.,
1997; Nazor et al., 2005), while other lines develop CNS disease
but apparently no infectivity (Chiesa et al., 1998; Hegde et al.,
1999). The spontaneous production of de novo prions was previ-
ously reported in just one case, for a randomly integrated trans-
gene with the P101L mutation (Hsiao et al., 1994). However, the
recipient animals for the inoculum overexpressed this same
mutation at a lower level (Hsiao et al., 1994). In repetitions of
this experiment, such animals spontaneously developed disease
without inoculation (Nazor et al., 2005), and disease could not be
transmitted to mice not carrying the mutation (Hsiao et al., 1994;
Nazor et al., 2005). This result was therefore reinterpreted to indi-
cate that the inoculum merely accelerated the course of disease
in mutant animals (Collinge and Clarke, 2007; Nazor et al., 2005).
Our ki-3F4-FFI mice were developed by replacing the endog-
enous PrP coding sequence with a PrP protein carrying the
D177N mutation in the coding sequence, but leaving all of the
native gene regulatory elements unchanged. It may be that PrP
needs to be expressed in particular cell types at particular levels
in order to generate the transmissible agent spontaneously.
Indeed, changes in regulation driven by Prnp’s endogenous
regulatory sequences in response to pathology may also play a
role. In any case, the fact that such an agent was generated
with endogenous levels of expression fulfills the prion hypothesis
rigorously.
An approach like ours was, however, used to model GSS with
the P101L mutation. Those mice did not get sick and did not
generate a transmissible agent (Manson et al., 1999). One expla-
nation for the difference in our results is that, in contrast with
D177N, P101L is not located in the structured core of PrP
(Riek et al., 1998). Thus, it might not be subject to the same
type of misfolding as our D177N mutation. Notably, both GSS
and FFI typically appear in humans in mid-life. However, once
pathology occurs, GSS progresses much more slowly than FFI
(average time to mortality 5 years after onset versus 1 year) (Ko-
vacs et al., 2002). In mice, given their short lifespan, it might
progress too slowly to manifest a detectable disease or to
generate infectious material.
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enhance the effect of the D177N mutation on the misfolding of
PrP. If so, then it is important that we included it, as it is present
in the human sequence, the natural context of the FFI mutation.
Importantly, the presence of this two amino acid substitution
does not itself influence the stability of PrP (as judged by its
steady-state accumulation and modification). And it does not
cause disease nor produce infectivity, even when mice are
aged for 2 full years to maximize the possibility of their producing
infectious agents if they were so prone. Thus, even if the 3F4
epitope facilitates the production of a transmissible agent, the
process is clearly driven by the FFI mutation.
Surprisingly, transgenic mice expressing high levels of fully
human PrP carrying familial mutations were recently reported
to be disease free (Asante et al., 2009). It may be that knockin
mice will be required, with PrP regulated by its endogenous
gene-regulatory elements. Alternatively, it might be necessary
to employ chimeric mouse-human PrP proteins to sufficiently
model inherited human prion diseases. Indeed, previous exper-
iments employing mice to test for the presence of a transmissible
agent in brain samples from humans with familial disease estab-
lished that chimeric proteins were much more effective than
either fully human or fully mouse proteins (Telling et al., 1995,
1996). A particularly interesting explanation is that mouse-
specific interaction sites for PrP cofactors or chaperones are
required. Knockin mouse experiments testing the FFI mutation
in the context of fully mouse or fully human PrP will begin to
address this interesting issue but, alas, will require an additional
5–6 years for completion.
Interestingly, a new randomly integrated transgenic mouse
model was recently reported to have sleep abnormalities (Dos-
sena et al., 2008; Fioriti et al., 2005). This transgene carried the
D177N mutation and the 3F4 epitope, but it also carried the
CJD-specific M128V polymorphism. However, in contrast with
our study, transmissible prions were not reported. Moreover,
the neuronal loss and spongiform degeneration characteristic
of CJD (Gambetti et al., 1995) were not reported (Dossena
et al., 2008). It would be interesting to compare our FFI knockin
mice with the randomly integrated FFI transgenics produced by
the same group (Fioriti et al., 2005). But neither spontaneous
disease nor the spontaneous generation of a transmissible agent
has yet been reported for them.
Prion infectivity experiments with knockin mice by their very
nature take a long time. These experiments were initiated 6 years
ago (18 months to target embryonic stem cells and derive stable
colonies, 18 months for knockin mice to develop full-blown age-
dependent neurodegeneration, 3 years for serial transmission).
Recently, another paper reported the spontaneous appearance
of infectivity from a variant PrP sequence (Sigurdson et al.,
2009). This contemporaneous study used very different methods
and sequences. It did not involve a familial mutation as did ours,
did not employ a species transmission barrier, and could only
transmit to mice overexpressing PrP (Tga20). Importantly,
however, it employed a cervid variant that is of great interest
from a public health standpoint (chronic wasting disease of
deer and elk) (Sigurdson et al., 2009). Together, our work and
theirs establish unequivocally that small sequence changes in
PrP are sufficient to create a transmissible conformation.The primary reason to model human neurodegenerative
disease in mice is to generate a mammalian brain that undergoes
a similar neurodegenerative process as in humans, but this is
rarely accomplished. In addition to providing important new
insight for prion biology, our mice develop biochemical, physio-
logical, behavioral, and neuropathological abnormalities remi-
niscent of the human disease. These mice will be an invaluable
resource in studies to uncover the mechanism of action of FFI
and for test trials of potential treatments for this dreaded
disease.
EXPERIMENTAL PROCEDURES
Mutagenesis of ES Cells
Our double-replacement gene-targeting strategy (Selfridge et al., 1992) was
similar to one described previously for the Prnp gene (Moore et al., 1995) but
with a few changes (Supplemental Experimental Procedures and Figure S1).
Western Blotting
Brains were homogenized using safe-grind tissue grinders (Wheaton, Millville,
NJ), in standard buffer (PBS supplemented with 150 mM NaCl, 1% Triton
X-100, 4 mM EDTA), and mini protease inhibitor cocktail tablets (Roche, Indi-
anapolis, IN). For PNGaseF and EndoH experiments, 10% homogenates
(100 mg/ml tissue; 10 mg/ml protein) were made in a hypotonic lysis buffer
(10 mM Tris pH 7.5; 10 mM NaCl; 3 mM MgCl2; 0.05% NP40; plus Roche
protease inhibitor tablets). Reactions were set up as suggested by the supplier
(New England Biolabs) with PMSF added. Reactions were incubated for 3 hr,
although 1 hr was sufficient to appropriately remove the glycans from AMOG,
our internal control. Reactions were stopped by adding 50 ml 43 Stop buffer.
20 ml (50 mg of total protein) were used per lane for electrophoresis. Several
attempts to perform reactions overnight resulted in reduction of total PrP
signal, indicating long incubations at 37C results in degradation of PrP
despite the addition of multiple protease inhibitors. For PK experiments,
10% brain homogenates made in PBS, then diluted into 23 conversion buffer,
resulting in 300 mM NaCl, 1% Triton X-100, 4 mM EDTA, and 0.1 M phosphate
buffer. Total brain protein was incubated at a concentration of 5 mg/ml and
was incubated at 37C for 30 min with 25 mg/ml enzyme grade PK.
Anti-PrP antibodies SAF32 (1:1,000; Cayman Chemical, Ann Arbor, MI),
SAF61 (1:1,000; Cayman Chemical, Ann Arbor, MI), SAF 83 (1:2,000; Cayman
Chemical, Ann Arbor, MI), 3F4 (1:1K), 6H4 (1:5,000; Prionics, Schlieren,
Switzerland), 7D9 (1:2,000; Abcam, Cambridge, MA). If scrapie-infected
samples were probed, then antibodies were diluted an additional 5-fold. Other
primary antibodies used: AMOG (adhesion molecule on glia or Na+, K+ ATPase
subunit beta 2; 1:10K) and anti-actin (1:3000; Sigma, St. Louis, MO). The actin
primary antibody was a rabbit polyclonal, and all others were mouse mono-
clonal. Blots in Figure 1 were probed with secondary antibodies labeled with
infrared fluorescent probes and scanned with the Odyssey imaging system
(LI-COR Biosciences, Lincoln, NE). Blots in Figures 2 and 5 were probed
with horseradish peroxidase labeled secondary antibodies and exposed to
film.
Transmission Experiments
Brains were homogenized with unused safe-grind tissue grinders, in 10
volumes of PBS. Experimental and control homogenates were sonicated
(Misonix processor XL, Farmingdale, NY) using a cup horn set to power 9 for
two 1 min pulses. Prior to injection into recipient mice, homogenates were
diluted to a specific concentration in PBS with 2% fetal bovine serum and soni-
cated for 1 min at power 9. Homogenates were injected either intracranially
(30 ml) or intraperitoneally (100 ml) using sterile 26 gauge needles into isoflur-
ane-anesthetized mice. A guide limiting the needle depth to 3.5 mm was
used for intracranial injections. Inoculants from scrapie-infected mice varied
in concentration from 0.001% to 1%, as indicated on graphs, while all inocu-
lants from spontaneously sick ki-3F4-FFI or ki-3F4-FFI infected mice were 1%,
diluted in PBS only. Spontaneously sick ki-3F4-FFI mice were injected into
tga20 mice homozygous for the transgene array for the first two experimentsNeuron 63, 438–450, August 27, 2009 ª2009 Elsevier Inc. 447
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for general markers of poor health (kyphosis, ataxia, priapism, coarse coat,
etc.) two to three times per week for scrapie experiments and three to four
times per month for FFI transmission experiments. Graphs depict time to
terminal illness for scrapie experiments and time until clear neurological
disease in FFI experiments (two or more symptoms or a specific symptom
on repeated health checks, since some were not terminally symptomatic prior
to the end of the experiments. Neuropathology investigation verified neurode-
generative disease.
Neuropathology
Fixed brain tissues were embedded in paraffin prior to cutting into 4 mm
sections, some of which were then stained with hematoxylin and eosin. We
often preserved mouse brains by emersion fixation in formalin (Sigma), as
this method allowed us to freeze one hemisphere as well. We also routinely
transcardially perfusion fixed brains using formalin (Sigma), paraformaldehyde
(Sigma), or Bouin’s fixative (RICCA chemical co., Arlington, TX). The same
neuropathological changes were detected regardless of the fixation method
used. Thirty-micron sections of formalin-fixed brains were also cut using a
vibratome. Vibratome sections were subsequently stained with a fluorescent
Nissl stain (Molecular Probes, Invitrogen).
IHC was performed on 4 mm paraffin-embedded sections. Sections were
dewaxed in zylenes and rehydrated in graded dilutions of ethanol. Epitope
retrieval was performed with microwave irradiation in 0.01 M citrate buffer.
After removing endogenous peroxidase and blocking in 4% normal horse
serum, samples were incubated with primary antibody in 2% serum/PBS over-
night at 4C in a wet incubation chamber. Samples were then incubated for 1 hr
at room temperature with a biotinylated secondary antibody followed by incu-
bation for 1 hr at room temperature with streptavidin-peroxidase (Vectastain
Elite ABC kit [Universal, PK-6200]), with thorough PBS washing between incu-
bation steps. A nickel-enhanced diaminobenzidine substrate (Pierce, Rock-
ford, IL) was used for detection. Primary antibodies: anti-PrP SAF32, 1:100
(Cayman Chemical, Ann Arbor, MI); anti-GFAP ascites MAB360, 1:10,000 dilu-
tion (Chemicon, Temecula, CA).
Magnetic Resonance Imaging
For magnetic resonance imaging, we used a contrast enhancement (Lin and
Koretsky, 1997) protocol we found capable of detecting subtle abnormalities
in a different mouse model of neurodegenerative disease (H.F. et al., unpub-
lished data). Mice were injected intraperitoneally with 37.7 mg/kg MnCl2,
1 day prior to imaging. For imaging, mice were anesthetized with isoflurane,
and motion was suppressed using a stereotaxic frame. Mice were imaged
on a Bruker 4.7 Tesla scanner using a surface coil and a T1-weighted gradient
echo pulse sequence (TE = 6 ms, TR = 50 ms, 6 averages) with a field of view of
2.03 2.03 1.0 cm and a matrix size of 1603 1603 80, for a total scan time of
64 min.
AMBA Recordings
Following weaning, mice were designated for behavioral experiments and
permanently housed in a suite of isolation cubicles dedicated to behavioral
experiments. Mice were video recorded at 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, and
24 months of age. Mice were housed in cages of up to four and were separated
from their cage mates into individual cages immediately prior to video
recording. The standard white lights automatically turn off after 1 hr of
recording and turn on after 13 hr of recording. Dim red lights, which rodents
do not see, illuminate the mice during the dark phase. After the 24 hr recording
period, mice were placed into fresh cages with their original cage mates. To
reduce the likelihood of fighting, especially upon reintroduction, only female
mice were used in AMBA experiments. More details, including definitions of
behaviors and validation tests of the software used, are described in Steele
et al. (2007).
Temperature Measurements
Core Tb was measured using iButtons model 1922L (Maxim, Dallas, TX), which
have a resolution of 0.067C. IButtons were implanted in the intraperitoneal
cavity of anesthetized mice. The first week after surgery was considered
a recovery phase, and data from this period were not considered.448 Neuron 63, 438–450, August 27, 2009 ª2009 Elsevier Inc.SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, two
tables of statistical data, six figures, and two movies and can be found with
this article online at http://www.cell.com/neuron/supplemental/S0896-6273
(09)00581-9.
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